20.01

0.20% -0.04

Teva Pharmaceutical Industries Ltd Adr (TEVA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché TEVA Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$20.05

Aprire:

$20.17

Volume 24 ore:

10.34M

Relative Volume:

0.93

Capitalizzazione di mercato:

$22.95B

Reddito:

$16.70B

Utile/perdita netta:

$-157.13M

Rapporto P/E:

-129.10

EPS:

-0.155

Flusso di cassa netto:

$1.19B

1 W Prestazione:

+9.11%

1M Prestazione:

+6.66%

6M Prestazione:

+34.75%

1 anno Prestazione:

+15.13%

Intervallo 1D:

$19.98

$20.61

Intervallo di 1 settimana:

$18.47

$20.61

Portata 52W:

$12.46

$22.80

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile

Nome

Teva Pharmaceutical Industries Ltd Adr

Settore

Healthcare (1145)

Industria

Drug Manufacturers - Specialty & Generic (85)

Telefono

972 (3) 914-8213

Indirizzo

TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV

Dipendente

35,686

Cinguettio

@TevaUSA

Prossima data di guadagno

2025-01-29

Ultimi documenti SEC

TEVA's Discussions on Twitter

Confronta TEVA con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TEVA Teva Pharmaceutical Industries Ltd Adr	20.01	23.00B	16.70B	-157.13M	1.19B	-0.155
ZTS Zoetis Inc	146.42	64.92B	9.39B	2.62B	2.22B	5.8121
TAK Takeda Pharmaceutical Co Adr	14.60	45.60B	29.96B	957.25M	4.77B	0.2956
HLN Haleon Plc Adr	8.95	39.54B	14.26B	1.98B	2.47B	0.4327
UTHR United Therapeutics Corp	453.07	20.06B	2.99B	1.21B	1.13B	25.06

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-06-06	Iniziato	Goldman	Buy
2025-05-28	Iniziato	Truist	Buy
2025-05-12	Aggiornamento	JP Morgan	Neutral → Overweight
2024-07-10	Aggiornamento	Argus	Hold → Buy
2024-03-08	Aggiornamento	JP Morgan	Underweight → Neutral
2024-02-12	Aggiornamento	Piper Sandler	Neutral → Overweight
2024-01-23	Aggiornamento	Jefferies	Hold → Buy
2024-01-03	Aggiornamento	Piper Sandler	Underweight → Neutral
2023-12-18	Iniziato	HSBC Securities	Buy
2023-11-27	Aggiornamento	UBS	Neutral → Buy
2023-07-06	Aggiornamento	UBS	Sell → Neutral
2023-05-25	Iniziato	Morgan Stanley	Equal-Weight
2023-05-18	Aggiornamento	Evercore ISI	In-line → Outperform
2023-01-19	Downgrade	Jefferies	Buy → Hold
2022-11-14	Downgrade	JP Morgan	Neutral → Underweight
2022-11-04	Downgrade	UBS	Neutral → Sell
2022-10-21	Ripresa	Jefferies	Buy
2022-08-05	Aggiornamento	BofA Securities	Neutral → Buy
2022-06-14	Ripresa	UBS	Neutral
2022-05-17	Aggiornamento	BofA Securities	Underperform → Neutral
2022-05-04	Downgrade	Piper Sandler	Neutral → Underweight
2022-04-05	Aggiornamento	Barclays	Equal Weight → Overweight
2022-03-25	Aggiornamento	Bernstein	Mkt Perform → Outperform
2022-01-27	Downgrade	Argus	Buy → Hold
2021-10-28	Downgrade	Raymond James	Outperform → Mkt Perform
2021-05-04	Downgrade	UBS	Buy → Neutral
2021-04-07	Ripresa	RBC Capital Mkts	Sector Perform
2020-11-25	Iniziato	Oppenheimer	Perform
2020-08-06	Aggiornamento	Barclays	Underweight → Equal Weight
2020-07-27	Ripresa	Goldman	Neutral
2020-06-01	Aggiornamento	SunTrust	Hold → Buy
2020-04-24	Ripresa	Citigroup	Neutral
2020-04-06	Aggiornamento	UBS	Neutral → Buy
2020-02-24	Downgrade	Edward Jones	Hold → Sell
2019-11-12	Aggiornamento	JP Morgan	Underweight → Neutral
2019-10-17	Aggiornamento	Gabelli & Co	Hold → Buy
2019-08-07	Downgrade	Evercore ISI	Outperform → In-line
2019-07-19	Iniziato	Wolfe Research	Peer Perform
2019-07-15	Downgrade	Morgan Stanley	Equal-Weight → Underweight
2019-07-10	Ripresa	Credit Suisse	Neutral
2019-07-05	Aggiornamento	Argus	Hold → Buy
2019-06-11	Iniziato	Barclays	Underweight
2019-06-03	Aggiornamento	Oppenheimer	Perform → Outperform
2019-05-30	Downgrade	BofA/Merrill	Buy → Underperform
2019-05-28	Downgrade	UBS	Buy → Neutral
2019-03-20	Iniziato	SunTrust	Hold
2019-03-07	Ripresa	UBS	Buy

Mostra tutto

Teva Pharmaceutical Industries Ltd Adr Borsa (TEVA) Ultime notizie

Sep 21, 2025

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed - Ariva

Sep 21, 2025

Sep 20, 2025

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction - Ariva

Sep 20, 2025

Sep 16, 2025

Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting - Sahm

Sep 16, 2025

Sep 14, 2025

Bayforest Capital Ltd Sells 3,875 Shares of Teva Pharmaceutical Industries Ltd. $TEVA - Defense World

Sep 14, 2025

Sep 09, 2025

Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - Ariva

Sep 09, 2025

Teva Pharmaceutical ADR Trying To Close In On Key Technical Measure - inkl

Sep 09, 2025

Aug 29, 2025

Teva stock rises on launch of first generic weight loss GLP-1 drug - Investing.com Nigeria

Aug 29, 2025

Aug 28, 2025

Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN

Aug 28, 2025

Teva stock rises on launch of first generic weight loss GLP-1 drug By Investing.com - Investing.com South Africa

Aug 28, 2025

Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss - Placera.se

Aug 28, 2025

Aug 21, 2025

TEVA Stock Price and Chart — TASE:TEVA - TradingView

Aug 21, 2025

Aug 18, 2025

Earnings call transcript: Teva’s Q2 2025 earnings beat fails to lift revenue - Investing.com

Aug 18, 2025

Aug 14, 2025

Nootropics Market Size Projected to Attain USD 19.53 Billion by 2034 - GlobeNewswire Inc.

Aug 14, 2025

Aug 13, 2025

Teva (TEVA) Is Up 5.7% After FDA Approves AJOVY for Pediatric Migraine Prevention - Sahm

Aug 13, 2025

Aug 12, 2025